3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Renal Cell
24
Kidney Neoplasms
10
Neoplasms
9
Carcinoma
6
Colorectal Neoplasms
5
Carcinoma, Hepatocellular
5
Carcinoma, Non-Small-Cell Lung
4
Recurrence
3
Neoplasm Metastasis
3
Melanoma
3
Thyroid Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Lung Neoplasms
2
Kidney Diseases
2
Glioblastoma
2
Carcinoma, Adenoid Cystic
2
Breast Neoplasms
2
Advanced Solid Tumors
2
cT2a N0NxM0 Renal Tumor
1
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Solitary Fibrous Tumors
1
Solid Tumors
1
Solid Malignancies
1
Skin Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Salivary Gland Neoplasms
1
Refractory or Recurrent Solid Tumors, Excluding CNS Tumors
1
Prostatic Neoplasms
1
Interventions
Rituximab
134
Cyclophosphamide
126
Peripheral Blood Stem Cell Transplantation
74
fludarabine phosphate
71
Filgrastim
62
Etoposide
56
Bortezomib
44
Vincristine
43
Mycophenolic Acid
43
Whole-Body Irradiation
42
Cytarabine
42
Cyclosporine
41
Melphalan
38
Doxorubicin
37
Radiotherapy
36
Busulfan
35
ibrutinib
34
Tacrolimus
34
Methotrexate
33
Prednisone
32
Lenalidomide
30
Bendamustine Hydrochloride
30
Antilymphocyte Serum
27
Dexamethasone
26
Carmustine
26
Granulocyte Colony-Stimulating Factor
23
ibritumomab tiuxetan
20
sargramostim
17
fludarabine
17
Methylprednisolone
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, Mantle-Cell
×
Axitinib
×
Clear all
NCT00700258
2024-09-23
STAR-TOR
Pfizer
Completed
1,520 enrolled
24 charts